Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy

Launched by CHANG GUNG MEMORIAL HOSPITAL · May 11, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how modern radiation therapy affects brain function and cancer control in patients with certain types of brain tumors called low-grade gliomas (LGGs). These tumors can be challenging to treat because they often grow in areas of the brain that are hard to reach. The trial aims to see how a specific type of radiation treatment impacts patients' memory and thinking skills while also helping to control the tumor's growth.

To participate, patients need to have already undergone surgery to remove part of their tumor and be recommended for radiation therapy due to certain high-risk factors, such as their age or the nature of their tumor. Participants will undergo brain scans and memory tests before starting treatment, which will take about 5 to 7 weeks. During this time, researchers will monitor changes in memory and other cognitive functions. This study is important as it seeks to balance effective treatment for brain tumors with the potential side effects on mental abilities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with infiltrative low-grade gliomas who have received craniotomy plus tumor removal or at least biopsy with pathologic conformation; brain radiation therapy is recommended owning to some high-risk features including subtotal resection (STR) or age at craniotomy older than 40 years old
• • Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 %
• Exclusion Criteria:
• • A pathological diagnosis confirmed to be WHO grade IV glioma (i.e., glioblastoma multiforme) or grade I disease (i.e., pilocystic astrocytoma)
• • Radiographic evidence of gliomatosis cerebri
• • Prior cranial irradiation for any reasons